Coronary artery calcium (CAC) scanning improves CVD risk stratification and informs statin decision-making in intermediate-risk adults
Summary
Major guidelines (2018 ACC/AHA Cholesterol, 2019 ACC/AHA Primary Prevention, 2021 ESC CV Prevention) endorse selective CAC scoring as a Class IIa decision-aid in borderline-to-intermediate-risk adults when statin benefit is uncertain. CAC score independently predicts MACE across MESA, Heinz Nixdorf Recall, and Rotterdam cohorts, reclassifies risk beyond pooled cohort equations, and CAC=0 confers a low short-to-medium-term event rate in that specific population. RCT evidence that CAC-guided decisions improve hard outcomes is limited (EISNER showed better risk-factor control; ROBINSCA ongoing); thus the utility claim is supported for decision-making and reclassification but indirect for MACE reduction. The post's position (skip CAC, just treat risk factors aggressively) is a defensible clinical style but is narrower than current guideline language, which explicitly lists CAC as a risk-refiner when the statin decision is uncertain.
Five-score assessment
Scope
- Low-risk adults <40 where CAC=0 is expected and does not rule out soft plaque
- Already-indicated high-risk patients (existing ASCVD, FH, LDL >=190) where statins are indicated regardless
- Symptomatic patients needing functional/anatomic ischemia testing
Evidence sources
Supporting (4)
-
Recommends CAC measurement (Class IIa) in borderline/intermediate-risk adults when statin decision is uncertain to refine risk and guide therapy.
-
Endorses CAC scoring as a risk modifier (Class IIb) in asymptomatic people with intermediate risk to reclassify ASCVD risk.
-
CAC score substantially improves discrimination and reclassification over pooled cohort equations in asymptomatic adults.
-
Randomization to CAC scanning improved systolic BP, LDL, waist, and framingham risk at 4 years vs no scan, with no increase in downstream testing costs.
Neutral / context (1)
-
Concluded insufficient evidence to assess balance of benefits/harms of adding CAC to traditional risk assessment for asymptomatic adults — direct outcomes evidence limited.